References

Agarwal R, Curley TM.  The Role of Statins in Chronic Kidney Disease.  Am J Med Sci.  2005;330:69-81.

Beddhu S, Kimmel PL, Ramkumar N, Cheung AK.  Associations of Metabolic Syndrome with Inflammation in CKD: Results from NHANES III.  Am J Kidney Dis.  2005;46:577-586.

Chen J, Muntner P, Hamm LL, et al.  The Metabolic Syndrome and Chronic Kidney Disease in U.S. Adults.  Ann Intern Med.  2004;140:167-174.

Chobanian AV, Bakris GL, Black HR, et al.  The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 Report.  JAMA.  2003:289:2560-2572.

Kurella M, Lo JC, Chertow GM.  Metabolic Syndrome and the Risk for Chronic Kidney Disease Among Nondiabetic Adults.  J Am Soc Nephrol.  2005;16:2134-2140.

Manrique C, Lastra G, Whaley-Connell A, Sowers JR.  Hypertension and the Cardiometabolic Syndrome.  J Clin Hypertens (Greenwich).  2005;7:471-476.

Menon V, Greene T, Pereira A, et al.  Glycosylated Hemoglobin and Mortality in Patients with Nondiabetic Chronic Kidney Disease.  J Am Soc Nephrol.  2005;16:3411-3417.

National Kidney Foundation.  K/DOQI Clinical Practice Guidelines on Hypertension and Antihypertensive Agents in Chronic Kidney Disease.  Am J Kidney Dis.  2004;43:S1-S290.

National Kidney Foundation. K/DOQI Clinical Practice Guidelines for Chronic Kidney Disease: Evaluation, Classification and Stratification.Am J Kidney Dis 39:S1-S266, 2002 (suppl 1).

National Kidney Foundation. KEEP 2004 Annual Data Report.Am J Kidney Dis 45:S1-S134, 2005 (suppl 2).

Neutel JM, Saunders E, Bakris GL, et al.  The Efficacy and Safety of Low- and High-Dose Fixed Combinations of Irbesartan/Hydrochlorothiazide in Patients with Uncontrolled Systolic Blood Pressure on Monotherapy: the INCLUSIVE Trial.  J Clins Hypertens (Greenwich).  2005;7:578-586.